Early postoperative serum cystatin C predicts severe acute kidney injury following cardiac surgery: a post-hoc analysis of a randomized controlled trial by Arndt-Holger Kiessling et al.
Kiessling et al. Journal of Cardiothoracic Surgery 2014, 9:10
http://www.cardiothoracicsurgery.org/content/9/1/10RESEARCH ARTICLE Open AccessEarly postoperative serum cystatin C predicts
severe acute kidney injury following cardiac
surgery: a post-hoc analysis of a randomized
controlled trial
Arndt-Holger Kiessling1*, Juliane Dietz1, Christian Reyher2, Ulrich A Stock1, Andres Beiras-Fernandez1
and Anton Moritz1Abstract
Objective: Acute kidney injury (AKI) after cardiac surgery procedures is associated with poor patient outcomes.
Cystatin C as a marker for renal failure has been shown to be of prognostic value; however, a wide range of its
predictive accuracy has been reported. The aim of the study was to evaluate whether the measurement of pre- and
postoperative serum cystatin C improves the prediction of AKI.
Methods: In a single-centre, prospective study of 70 patients (74 ± 9ys; range 47-85ys; 77% male), cystatin C was
measured six times: (T1 = preoperative, T2 = start cardiopulmonary bypass (CPB), T3 = 20 min after CPB, T4 = end of
operation; T5 = 24 h postoperatively; T6 = 7d postoperatively). Predictive property, in terms of the need for renal
replacement therapy (RRT), was analysed by receiver operating characteristics (ROC) statistics and described by the
area under the curve (AUC).
Results: With respect to RRT (n = 8), serum cystatin C was significantly higher at the end of the operation (T4), 24 h
postoperatively at T5 and at T6. The AUCs for preoperative T1 and intraoperative T2/3 cystatin C were <0.7 (95% CI,
0.47-0.85). The earliest significant predictive AUCs were found at the end of the operation (T4: p = 0.03 95% CI
0.58-0.88 AUC 0.73) and 24 h postoperatively (T5: p = 0.003 95% CI 0.74-0.96 AUC 0.85).
Conclusions: Early postoperative serum cystatin C increase appears to be a moderate biomarker in the prediction
of AKI, whereas a preoperative and intraoperative cystatin C increase has only a limited diagnostic and predictive
value.
Keywords: Cystatin C, Cardiac surgery, Cardiopulmonary bypass, Acute kidney injuryBackground
Particularly in the case of pre-existing renal disease and
complex surgical procedures, acute kidney injury (AKI)
is a frequently observed complication of heart surgery
(5-10%) [1-3]. AKI is associated with increased mortality
and ventilation time and longer stays in the ICU and
hospital [2]. Criteria for diagnosing AKI are based on the
relative or absolute serum creatinine fluctuations [4] and
urine excretion. The disadvantage of these non-specific* Correspondence: cardiac.surgeon@dr-kiessling.com
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reproduction in any medium, provided the ormarkers is their delayed appearance in particular.
Serum creatinine is also affected by non-renal factors
such as muscle mass, distribution volume and tubular
secretion [4].
A series of new, alternative markers which are said to
detect renal function as well as the appearance of acute in-
sufficiency earlier and more accurately has been published.
One of these new markers is cystatin C (CysC), a 13-kD
cysteine protease inhibitor protein which is formed in all
cells with a cell nucleus. In contrast to creatinine, it does
not undergo tubular filtration but instead glomerular
filtration and it is not subject to any significant protein
binding. CysC has shown that it can accurately indicatel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, various extrarenal factors can distort and affect
cystatinC values. These include for example the thyroid
function or the administration of glucocorticosteroids,.
The mean reference serum cystatin C level is 0.84 mg/L
in non-Hispanic adolescents and normal renal function
[5]. It is not known how ultrafiltration during extracor-
poreal circulation affects serum CysC levels [6].
Studies were able to demonstrate that CysC is a good
prognostic factor for the duration and severity of AKI
following aortic valve replacement, coronary angiography
and complex cardiac-surgery procedures [7-9]. The ques-
tion of at what point postoperatively increases in CysC
are predictive in nature is unclear. From this we formu-
lated the main question of the study: from when and with
which RIFLE definition [10] can CysC levels predict AKI




This study is a post-hoc analysis of a study that has already
been published which was primarily designed to detect
differences in the preoperative coating of the CPB
(NCT01247051). We recruited 70 patients with elective on-
pump cardiac-surgery procedures at the Johann Wolfgang
Goethe University Hospital (Frankfurt am Main, Germany)
in the period from the first quarter of 2011 to the third
quarter of 2011. A written informed consent form was
obtained from all patients. The study was appoved by the
local ethic committee (No:143/10). Inclusion criteria were
patients with normal renal function,age of >75 years and/or
a reduced left ventricular function of <40%. Furthermore,
informed consent and elective, planned surgery using the
heart-lung machine was needed. Patients with combined
interventions on the aorta and/or carotid arteries and/
or multiple valve operations were excluded. Patients
were similarly not included into the study if the follow-
ing preoperative exclusion criteria were present: serum
creatinine >1.8 mg/dl, raised GOT/GPT values double
the norm, haemoglobin (Hb) <11 mg/dl, myocardial
infarction within the last seven days before surgery and
affiliation to the religious community of the Jehovah’s
Witnesses [11].
Data and sample collection
The preoperative patient data were collected 24 hours
before the surgery. In addition to routine clinical care
parameters, they also covered study-specific parameters
which can affect the cystatin value. These included the
GFR, administration of cortisones, thyroid function values
(TSH), and C–reactive protein (C-rP). Intraoperatively,
CPB parameters (cardiac index, CPB time, ACC time,
urine excretion, type of ultrafiltration) were added to thedata. Furosemide and exogenous steroid administration
was recorded until the second postoperative day. The
postoperative volume status was calculated using patient
weight and fluid balance.
Laboratory testing
Six measurement time points (T1 preoperative, T2-4 intra-
operative, T5-6 postoperative) were defined. The blood
samples were stored on ice and centrifuged at 4°C at
4000 rpm for 15 minutes. The serum samples were then
stored at −20°C. The analysis was performed in the central
laboratory of the Centre for Internal Medicine and the
study laboratory of the Department of Thoracic and
Cardiovascular Surgery of Johann Wolfgang Goethe
University hospitals in Frankfurt am Main (recognition
according to DIN EN ISO 15189; DIN EN ISO 9001:2008
accreditations of medical laboratories). Serum cystatin C
was determined by means of an immunoassay (Bühlmann,
Germany). The lower limit of detection was 0.05 mg/L.
The clinical parameters are based on the evaluations of
the German federal cross-sector quality assurance associ-
ation (SQG, Aqua Institut Göttingen, Germany) and were
taken from existing postoperative databases.
Endpoint definition
The primary endpoint was the new occurrence of acute
kidney injury within 48 h after the end of the surgery. We
chose a brief observation period, since prior studies have
demonstrated that AKI occurs within the first 24-48 h
after use of extracorporeal circulation [12]. In the primary
analysis, we defined AKI as the use of renal replacement
therapy (RRT-AKIN3). In a secondary analysis, AKI was
defined as an increase of 50% or 0.3 mg/dL over the base-
line creatinine value (AKIN1). This interpretation corre-
sponds to the Acute Kidney Injury Network criteria [4].
An additional AKI criterion of the Acute Kidney Injury
Network is oliguria (urine excretion <0.5 mL/kg/h for 6
hours) [4]. This criterion is difficult to describe in the
postoperative, cardiothoracic care. Due to intravenous
fluid administration and diuretic application, the diagnosis
of an AKI by oliguria could be masked by the individual
ICU therapies. The urine output was nevertheless re-
corded at all measurement time points [10].
Statistical analysis
Continuous variables with normal distribution were evalu-
ated using the unpaired t test and variables with non-
normal distribution were evaluated using the Wilcoxon
test. Categorical variables were measured with the χ2
and Fisher’s exact test. CysC was compared at each
measurement time point with the unpaired t test.
Serial CysC measurement values were compared in
patients with and without AKI with a linear mixed
correlation. We calculated receiver operating characteristics
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The area under the curve (AUC) with an associated
95% confidence interval (CI) was used as a measure-
ment for the discriminating capacity of CysC to predict
AKI. An ROC AUC value of 0.60-0.69 demonstrates a
poor predictive value, 0.70-0.79 a moderate predictive
value, 0.80-0.89 a good predictive value and 0.90-0.99
an excellent predictive value. Logistic regression was
calculated to evaluate whether increasing CysC values
are implicated, independently of the development of
an AKI. Preoperatively, we defined variables which
are implicated as confounders of AKI [1]. The final
model was calculated in incremental methods of selec-
tion whereby the inclusion of a variable with P < 0.10
in the model was permissible. Since CysC can be
increased in patients with chronic renal disease (GFR
<60 mL (min/1.73 m2), these data were not included in
the analysis. All analyses were calculated using the
IBM SPSS version 20.0 (New York, USA). A two-sided
P value of <0.05 was considered to be statistically





Age ys 72.6 ± 10.1
Weight kg 83 ± 15
Baseline Crea mg/dl 1.09 ± 0.3
Baseline GFR stage 2.2 ± 0,6
Elective% (n) 100(62)
ASA class ≥II% (n) 34(21)
Diabetes% (n) 29(18)
LV function reduced% (n) 53(33)
Surgical data
Bypass time min 116 ± 39
Cross-clamp time min 72 ± 32
Urine output on bypass ml 360 ± 290
Post-filtration CPB% (n) 8(5)
CABG% (n) 62(39)
Postoperative data
Fluid balance 24 h ml 1103 ± 1026
Furosemide total dose 48 h (mg) 90 ± 60
Secondary outcome
Length ICU stay d 1,58 ± 1.89
Length hospital stay d 11 ± 5.9
Mortality 30d% (n) 6.4(4)
Significant differences were found in CPB times, length of hospital and ICU stay andResults
Clinical outcome
All blood draws were able to be performed on 70 patients.
Three other patients were not included in the analysis.
This was due to a lack of preoperative blood values.
Twenty-one patients developed AKI according to creatin-
ine criteria (AKIN 1); 8 patients had to be treated with
renal replacement therapy. Preoperative, baseline and
postoperative characteristics are shown in Table 1. CPB
time and aortic clamping time were significantly longer in
patients who developed AKI. Patients with AKI were older
(p = 0.003) and demonstrated a trend towards higher pre-
operative creatinine values (p = 0.13). Patients with AKI
have a poorer clinical outcome, including length of stay in
the ICU and hospital (Table 1). The indications for and
timing of a dialysis procedure were not standardised in
the protocol and were individual medical decisions. The
main reason for an acute dialysis therapy was an anuresis
in the first postoperative hours (n = 4) after the cardiac
procedure. Renal replacement therapy was initiated after
mean of 2.1 ± 1.9 days (range 0-4days) and terminatedal replacement therapy) and patients without any renal
AKI (renal replacement) p-value
75(6) 0.79
80 ± 3.7ys 0.003
87 ± 14 0.51
1.6 ± 0.84 0.13





155 ± 38 0.01
102 ± 36 0.02
315 ± 310 0.32
37(3)
25(2) 0.05
1403 ± 860 0.001
98 ± 65 0.4
23.25 ± 20.88 0.000
30.6 ± 19.1 0.000
25(2) 0.1
age.
Table 3 CystatinC kinetics in patients with renal
replacement therapy



























Early significant differences were found at the end of operation (p = 0.03).
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into a chronic program. The other dialysis indications
were potassium overload (n = 1) and respiratory failure
due to lung congestions (n = 3).
Cystatin C performance
In a linear mixed model in a paired comparison, CysC
values significantly differ in patients with and without
AKI starting at time point T4 (end of operation). The dif-
ference becomes increasingly more significant with the
time from the operation (Tables 2 and 3). Figure 1 shows
the longitudinal differences between time (t1-t6) and the
measured CysC values. Based on the baseline values,
there were significant differences for CysC at times T4/5/
6 (Table 3). Patients with AKI have a higher CysC level
over all measurement time points; however, the earliest
predictor of AKI was seen at time T4 (end of operation).
In the ROC analysis, CysC peaked on postoperative day 4
with 0.733 (95% confidence interval, 0.586-0.88). All earl-
ier times were poorer predictors of CysC and AKI (0.7).
All measurement times after T4 had a higher predictive
value. (T5 = 0.84, 95% CI, 0.739-0.960/T6 0.899, 95% CI,
0.779-1; all p-values <0.05). On the other hand, if patients
with AKI are defined not only with the hard criterion of
renal replacement therapy, but if patients with a 50% in-
crease in creatinine are added (AKIN 1), then the size of
the group increases from 8 to 21. With the increase in
the number of patients, however, the predictive value of
CysC also decreases. At no time is there a moderate to
good predictive value (ROC >0.8) for the connection be-
tween CysC and the expanded definition of AKI (Table 4).
Highly significant correlations (p < 0,001) with serum
creatinine (Scr) and blood urea nitrogen (BUN) were
found at any time points Table 5. These comparisons
suggest that CysC is not superior to the routine markers
(Scr/BUN).Table 2 CystatinC kinetics in patients with AKIN1

























Late significant differences were found on POD 1 and discharge (POD 6).CysC and influencing factors
Ultrafiltration, priming of the CPB and fluid balance do
not affect the kinetics of CysC. In all patients, the pre-
operative baseline value falls by a median 20% after the
start of the CPB and increases back up to the baseline level
by the end of the operation, independently of the perfusion
methods used. Then, in the following 48 h, the values in-
crease (median 23%) above the preoperative baseline value.
Eleven patients received intra- and early postoperative
corticosteroids. There was no connection between the
steroid dose and CysC at T5 or later T6. No increase
in CysC was detected in these patients. In nearly all
patients, preoperative TSH values demonstrated a nor-
mal thyroid metabolic status. Analyses outside of theFigure 1 Shows the longitudinal differences between time
(t1-t6) and the measured CysC values in patients with and
without postoperative renal replacement therapy.
Table 4 Moderate to good prognostic AUC values for
CystatinC were found in patients with renal replacement
therapy at T4 to T6
CystatinC (N = 70) Time AKI (AKIN 1) AKI (renal replacement
therapy
T1 preoperative 0,553 (CI:0,4-0,7) 0,659 (CI:0,47-0,84)
T2 start CBP 0,565 (CI:0,41-0,71) 0,671 (CI:0,5-0,84)
T3 20 minutes after
CBP start
0,528 (CI: 0,37-0,67) 0,650 (CI:0,45-0,84)
T4 OP-end 0,63 (CI:0,49-0,77) 0,733 (CI:0,58-0,88)
T5 24 h postoperative 0,72 (CI:0,58-0,86) 0,849 (CI:0.73-0,96)
T6 discharge (max.
day 6)
0,7 (CI:0,53-0,87) 0,899 (CI:0,77-1,0)
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provide any evidence that high or low TSH values influ-
ence CysC kinetics.
Discussion
Following cardiac-surgery procedures, serially measured
serum CysC concentrations are positively associated with
the onset of postoperative renal failure. CysC values mea-
sured immediately at the end of the operation provide an
early indication of the possible onset of AKI. However,
the predictive value depends on the AKI definition,
according to whether renal replacement therapy or the
increase in creatinine (AKIN 1) is used for this purpose.
This may also explain the weakness of CysC, namely that
it is not possible to predict before surgery whether the
patient will develop AKI postoperatively.
Our results are comparable with those of other studies
which confirm the reliability of CysC as a marker of renal
function [13,14], particularly when an CPB is used [15-17].
Our data support the expanded indication of CysC as a
marker of glomerular filtration as well as of chronic and
acute renal insufficiency. CysC is an attractive marker for
assessing GFR [17]. CysC is synthesized by all nucleated
cells and, in contrast to creatinine, which is produced by
muscle cells, CysC is not affected by the interindividual
differences and intraindividual changes in the muscle mass.
In addition, CysC is filtered at glomerular level and metabo-
lised without undergoing tubular secretion or reabsorption.Table 5 Good prognostic AUC values for creatinine were
found in patients with renal replacement therapy at any
timepoint
Creatinine (N = 70) Collection
time
AKI (renal replacement therapy)
TX1 postoperative day 1 0,876 (CI:0,72-1,00)
TX2 postoperative day 2 0,904 (CI:0,797-1,00)
TX3 postoperative day 3 0,904 (CI:0,784-1,00)
TX4 postoperative day 4 0,928 (CI:0,816-1,00)It is noteworthy that CysC concentrations differ in patients
with and without AKI at all time points. The decrease dur-
ing CPB can be explained by haemodilution [18] and for
the immediate postoperative increase there is a correlation
between CysC and C-reactive protein as a direct marker of
CPB-induced inflammation [19].
Current studies remain unclear with regard to the bene-
fit of CysC, however. Our finding regarding a limited
benefit of CysC as an early marker of AKI is identical to
the observations of Koyner et al. [20]. The CysC values of
70 patients with CPB were determined upon arrival in the
ICU. With an AUC for the development of AKI (defined
as a serum creatinine increase of 50% as compared to the
baseline value) of 0.62 (95% CI, 0.48 to 0.75), there is a
slight CysC-AKI association. This can be explained by the
work of Rosner et al. and Moran [2,21], who see CPB-
associated AKI as being mediated by damage to the renal
tubules, whereas CysC is a marker of glomerular filtration.
As a result of tubular damage, upstream glomerular filtra-
tion can be impacted due to congestion and can explain
an increase in CysC.
However, other studies support the utility of CysC as
an early predictor of AKI. In a cohort of critically ill pa-
tients, serum cystatin C demonstrated the occurrence of
a creatinine-based AKI 1 to 2 days earlier than an estab-
lished marker [22]. In a recently published study of 100
patients with CPB, the predictive capacity of plasma
CysC upon arrival at the ICU was excellent (AUC 0.83,
95% CI, 0.68 to 0.98) [23]. The reasons for the discrep-
ancy are not entirely clear. On the one hand, the perfu-
sion techniques may differ with regard to haemodilution
and post-filtration. On the other hand, the definition of
AKI remains very variable and, finally, the CysC meas-
urement times are different. A meta-analysis by Zhang
et al. [23] was able to identify 15 studies which investi-
gated the predictive value of CysC. A high OR of 23.5/
95% CI, 14.2-38.9 = for serum CysC was found across all
different study endpoints. Five studies were performed in
a cardiac-surgery population. The pooled AUC was 0.96
(95%0.95.0.97), which corresponds to a very good correl-
ation with AKI. In this review, Zhang concluded that
serum CysC is an outstanding predictor of the onset of
AKI, irrespective of the population investigated (sepsis,
cardiac surgery). The superiority to serum creatinine is
the non-dependence on age, sex, muscle mass and earlier
onset. In a multicentre, prospective study of the Tribe-AKI
(Translational Research Investigating Biomarker endpoints
for Acute Kidney Injury) consortium [24] published in July
2012, it was found, in contrast to Zhang [25], that in the
case of creatinine-defined AKI (cardiac surgery), sensitivity
and specificity were lower for CysC than for serum creatin-
ine. However, the sampling times differ from our results.
Spahillari et al. [24] did not collect blood samples until
24 h after the operation but concluded that there were no
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study are, firstly, patient selection. Due to the post-hoc
sub-analysis, no urgent and complex procedures (e.g.
triple valves, aortic surgery, redo’s) were included in the
evaluation. On the other hand, blood sampling times in a
narrower postoperative interval would have been of use.
AKI was only defined by creatinine increase and not by
the second criteria of a decreasing urine output. Patients
who develop AKI have higher rates of mortality and
resource utilization, with the worst values seen in dialyzed
patients. Emerging evidence suggests that even small
changes in creatinine after cardiac surgery are associated
with significant effects on mortality. Whether AKI directly
causes adverse outcomes is not entirely clear; however, an
increase in infection and new-onset sepsis, congestive
heart failure, and fluid overload may be contributory [1].
Traditional biomarkers of AKI (creatinine and urea)
increase slowly in response to renal injury, are insensitive
to mild degrees of AKI, and are influenced by nonrenal
factors. There is considerable interest in novel biomarkers
of AKI such as cystatine c that increase rapidly after renal
injury, detect mild degrees of AKI, and are less subject to
nonrenal factors. It has been postulated that the early
diagnosis of cardiac surgery-associated AKI using novel
biomarkers will result in improved outcomes. However,
there is little evidence that interventions started early in
the course of evolving AKI enhance renal recovery. Until
effective therapies are developed that significantly improve
the outcome from AKI, there is little benefit from early
diagnosis using novel biomarkers [25,26].
Conclusion
In summary, we were able to calculate a subanalysis of the
connection between CysC and AKI in our prospective
study. The early predictive value can only be evaluated
when AKI is defined as renal replacement therapy. By
contrast, in the case of an AKIN 1 stage (increase in cre-
atinine >50% baseline value), no good statistical connections
can be detected. Cystatin can be determined as an additional
parameter in cardiac-surgery procedures; however, the cost-
effective and simple determination of the serum creatinine
value continues to be the routine recommendation. A pro-
spective, randomised study with prophylactic dialysis as an
indication in one study arm may potentially provide a new
starting point for the validity of CysC in clinical use.
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